Abstract 337P
Background
T and NK-cell lymphoma represents approximately 10 to 15% of all non-Hodgkin’s lymphoma worldwide. However, the epidemiology of underlying subtypes varies geographically. As such, we aim to investigate disease patterns, patient demographics and survival outcomes in a multiethnic cohort from Singapore.
Methods
We performed a retrospective analysis on various histological subtypes of T and NK-cell lymphoma diagnosed from 2004 to 2022 (n=325) at the National Cancer Centre Singapore. Clinico-demographic data were collated across major ethnic groups (Chinese, Malay and Indian) and pre-defined age groups (<40, 40-65, and >65 years). Overall survival was estimated using the Kaplan-Meier method.
Results
In our study cohort, the median age was 55 years (range, 15-88), with a male predominance (61.2%). Major ethnic groups include Chinese (72.0%), followed by Malays (10.5%) and Indians (4.6%). In terms of age at diagnosis, the majority presented between ages 40 to 65 years (50.8%) in comparison to other age groups (<40 years, 24.0%) and (>65 years, 25.2%). The most common histological subtypes include angioimmunoblastic T-cell lymphoma/peripheral T-cell lymphoma T-follicular helper phenotype (AITL/PTCL-TFH) (38.8%), natural killer/T-cell lymphoma (NKTCL) (17.2%), and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) (12.6%). In analysis by age groups, AITL/PTCL-TFH was the dominant diagnosis. The next most common diagnosis was NKTCL for patients above 65 years, and was PTCL-NOS in patients under 40 years. Further analysis of ethnic distribution amongst these common subtypes revealed a similar trend, though interestingly, NKTCL was not observed amongst the Indian subgroup. In the whole cohort, the median overall survival was 21.4 years with a 5-year OS of 75.6%. 5-year OS was significantly worse for PTCL-NOS as compared to AITL/PTCL-TFH or NKTCL (62.5% vs 79.2% and 78.5%, respectively; log-rank p=0.0225). Age at diagnosis, disease stage and IPI risk groups were significantly prognostic, but not ethnic groups and sex.
Conclusions
Through this analysis we identified unique demographic and survival patterns in T and NK-cell lymphoma within our local population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Tanoto Foundation Professorship in Medical Oncology New Century Foundation Limited Ling Foundation Singapore Ministry of Health’s National Medical Research Council Research Transition Award (TA21jun-0005) and Large Collaborative Grant (OFLCG18May-0028).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract